Novartis expects net sales to grow at a compound annual rate of 5% at constant currencies from 2026 through 2031, according to its updated outlook. The company said its core operating income margin is on track to return to 40% or higher by 2029 and projected mid-single-digit sales growth over the longer term.
Novartis raised its peak sales forecast for Kesimpta to $8 billion from $6 billion and lifted its forecasts for Scemblix and Leqvio to $5 billion apiece from $4 billion each. It had previously raised its projection for Rhapsido, or remibrutinib, to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis.
The company puts peak sales potential at $3 billion to $10 billion each for nine marketed assets or product groups. Along with Kesimpta, Scemblix, Leqvio and Rhapsido, the list includes Kisqali, Cosentyx, Pluvicto, Fabhalta, and the group comprising Zolgensma and Itvisma.
Novartis expects more than 35 study readouts through 2031 that could support regulatory submissions. The company highlighted more than 30 pipeline assets, including more than 20 in registration, Phase 3 or Phase 2, and more than 10 in or entering Phase 1. It projects multibillion-dollar peak sales for each of 10 late-stage assets.
Among the programs highlighted were abelacimab for stroke prevention in patients with atrial fibrillation, ianalumab for systemic lupus erythematosus and votoplam for Huntington’s disease. The company also highlighted pelabresib for myelofibrosis and its investigational radioligand therapy AAA817 for prostate cancer.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!